|
| Study (first author, year) | Subjects (herbal/control) | Stroke type (ischemic/hemorrhagic) | Interventions | Main outcomes (herbal/control) | Duration of outcome assessment (weeks) | Adverse events (herbal/control) |
| Herbal medicines | Control group |
|
| Song, 2011 | 70 (35/35) | 53/17 | Conventional therapies + rehabilitation therapies for stroke + BHT variant 1
4 weeks | Conventional therapies + rehabilitation therapies for stroke 4 weeks | FSS
3.15 ± 1.71/4.09 ± 1.86
IL-1β (23/19)
21.3 ± 9.5/26.7 ± 10.3 (pg/ml)
IL-6 (23/19)
16.2 ± 8.3/21.7 ± 9.2 (pg/ml)
TNF-α (23/19)
20.6 ± 14.3/29.8 ± 15.2 (pg/ml) | 4 | 0/0 |
| Liang, 2016 | 92 (46/46) | 57/35 | Conventional therapies + rehabilitation therapies for stroke + BHT variant 2
4 weeks | Conventional therapies + rehabilitation therapies for stroke 4 weeks | FSS
3.39 ± 0.73/5.33 ± 5.45 | 4 | Unreported |
| Xu, 2018 | 62 (31/31) | Unreported | Conventional therapies + rehabilitation therapies for stroke + BHT variant 3
4 weeks | Conventional therapies + rehabilitation therapies for stroke 4 weeks | TCER
29/31 (93.55%)/19/31 (61.29%) | 4 | Unreported |
| Yin, 2020 | 80 (40/40) | Unreported | Conventional therapies + rehabilitation therapies for stroke + BHT variant 4
4 weeks | Conventional therapies + rehabilitation therapies for stroke 4 weeks | FSS
3.27 ± 0.81/5.41 ± 0.56 | 4 | Unreported |
| Duan, 2021 | 60 (30/30) | Unreported | Conventional therapies + rehabilitation therapies for stroke + BHT variant 5
4 weeks | Conventional therapies + rehabilitation therapies for stroke 4 weeks | FSS
2.73 ± 0.23/3.81 ± 0.24 | 4 | Unreported |
| Ye, 2018 | 63 (33/30) | Unreported | BHT variant 5
4 weeks | Conventional therapies for stroke 4 weeks | FSS
2.73 ± 0.24/3.81 ± 0.24 | 4 | Unreported |
|
